. 2022 Feb 25;14(5):1214. doi: 10.3390/cancers14051214

Table 5.

The results of QoL assessment (EORTC QLQ-BR23) in patient groups differing with respect to the level of illness acceptance; and the results of the analysis of variance.

Functional Scales QLQ-BR23	Level of Illness Acceptance (AIS)			ANOVA p
	Low Acceptance 8–18 pts.	Moderate Acceptance 19–29 pts.	High Acceptance 30–40 pts.
	n = 32	n = 69	n = 101
Body image (BRBI)				<0.001
M ± SD	30.3 ± 25.9	46.3 ± 28.4	51.0 ± 25.2
Me (Q₁; Q₃)	25 [8; 33]	42 [25; 67]	54 [33; 75]
Min–Max	0–100	0–100	0–92
Sexual functioning (BRSEF)				0.001
M ± SD	29.2 ± 29.9	43.5 ± 29.6	47.4 ± 29.1
Me (Q₁; Q₃)	33 [0; 33]	33 [33; 67]	50 [33; 67]
Min–Max	0–100	0–100	0–100
Sexual enjoyment (BRSEE)				<0.001
M ± SD	14.7 ± 27.4	40.2 ± 31.7	46.1 ± 37.5
Me (Q₁; Q₃)	0 [0; 33]	33 [0; 67]	33 [0; 67]
Min–Max	0–100	0–100	0–100
Future perspective (BRFU)				0.010
M ± SD	70.8 ± 29.0	80.9 ± 26.6	66.7 ± 32.0
Me (Q₁; Q₃)	67 [33; 100]	100 [67; 100]	67 [33; 100]
Min–Max	33–100	0–100	0–100
QLQ-BR23 symptom scales
Systemic therapy side effects (BRST)				<0.001
M ± SD	41.8 ± 20.9	32.9 ± 19.7	22.9 ± 17.1
Me (Q₁; Q₃)	43 [28; 58]	29 [14; 43]	19 [10; 33]
Min–Max	5–76	0–100	0–71
Breast symptoms (BRBS)				<0.001
M ± SD	42.5 ± 30.2	33.7 ± 24.2	19.0 ± 20.8
Me (Q₁; Q₃)	46 [8; 67]	33 [8; 50]	8 [0; 33]
Min–Max	0–92	0–92	0–92
Arm symptoms (BRAS)				0.011
M ± SD	45.1 ± 23.5	37.4 ± 26.1	31.0 ± 22.5
Me (Q₁; Q₃)	44 [22; 58]	33 [11; 56]	22 [11; 44]
Min–Max	0–89	0–89	0–100
Upset by hair loss (BRHL)				0.141
M ± SD	54.7 ± 30.3	61.7 ± 35.9	46.8 ± 35.9
Me (Q₁; Q₃)	67 [33; 67]	67 [33; 100]	33 [33; 67]
Min–Max	0–100	0–100	0–100

M—mean; SD—standard deviation; Me—median; Q₁—lower quartile; Q₃—upper quartile; Min—lowest value; Max—highest value; n—number; values in bold indicate statistical significance (p < 0.05).